Neoadjuvant nivolumab improves long-term survival for lung cancer
Analysis of a Phase II trial for non-small cell lung cancer has suggested neoadjuvant nivolumab improved five-year recurrence-free survival.
United States Samuel Rosner Patrick Forde Bristol Myers Squibb National Institutes Of Health Johns Hopkins University Cancer Center
Source: europeanpharmaceuticalreview.com